Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis
Authors:
- Andreas Karlsson RosenbladARAndreas Karlsson Rosenblad
- Bassam Mazin HashimBHBassam Mazin Hashim
- Per LindbladPLPer Lindblad
- Börje LjungbergBLBörje Ljungberg
- the National Swedish Kidney Cancer Register Steering CommitteeTCthe National Swedish Kidney Cancer Register Steering Committee
Open Access
- 7 August 2024
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-9
Abstract
Purpose: To examine associations between ablative therapy (AT) and partial nephrectomy (PN) and the occurrence of local recurrence (LR), distant metastatic recurrence (DMR) and all-cause mortality in a nation-wide real-world population-based cohort of patients with nonmetastatic renal cell carcinoma (nmRCC). Methods: Data on 2751 AT- or PN-treated nmRCC tumours diagnosed during 2005–2018, representing 2701 unique patients, were obtained from the National Swedish Kidney Cancer Register. Time to LR/DMR or death with/without LR/DMR was analysed using Cox regression models. Results: During a mean of 4.8 years follow-up, LR was observed for 111 (4.0%) tumours, DMR for 108 (3.9%) tumours, and death without LR/DMR for 206 (7.5%) tumours. AT-treated tumours had a 4.31 times higher risk of LR (P < 0.001) and a 1.91 times higher risk of DMR (P = 0.018) than PN-treated, with no significant differences in risk of death without LR/DMR. During a mean of 3.2 and 2.5 years of follow-up after LR/DMR, respectively, 24 (21.6%) of the LR cases and 56 (51.9%) of the DMR cases died, compared to 7.5% in patients without LR/DMR. There were no significant differences between AT- and PN-treated regarding risks of early death after occurrence of LR or DMR. Conclusion: AT treatment of patients with nmRCC implied significantly higher risks of LR and DMR compared with PN treatment. To minimize the risks of LR and DMR, these results suggest that PN is preferred over AT as primary treatment, supporting the EAU guidelines to recommended AT mainly to frail and/or comorbid patients.Keywords
Funding Information
- Umea University
This publication has 31 references indexed in Scilit:
- Percutaneous radiofrequency ablation is an effective treatment option for small renal masses, comparable to partial nephrectomyEuropean Radiology, 2023
- A multicenter comparative matched-pair analysis of percutaneous tumor ablation and robotic-assisted partial nephrectomy of T1b renal cell carcinoma (AblatT1b study—UroCCR 80)European Radiology, 2023
- Impact of Partial Nephrectomy and Percutaneous Cryoablation on Short-term Health-related Quality of Life—A Prospective Comparative Cohort StudyEuropean Urology Open Science, 2022
- A psychometric evaluation of the Functional assessment of cancer therapy—kidney symptom index (FKSI-19) among renal cell carcinoma patients suggesting an alternative two-factor structureQuality of Life Research, 2021
- Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline PanelEuropean Urology Oncology, 2020
- Features of Ipsilateral Renal Recurrences After Partial Nephrectomy: A Proposal of a Pathogenetic ClassificationClinical Genitourinary Cancer, 2017
- Mortality, morbidity and healthcare expenditures after local tumour ablation or partial nephrectomy for T1A kidney cancerEuropean Journal of Surgical Oncology, 2017
- Skin Tumours2017
- Long-Term Oncologic Outcomes After Radiofrequency Ablation for T1 Renal Cell CarcinomaEuropean Urology, 2013
- Metastatic Potential in Renal Cell Carcinomas ≤7cm: Swedish Kidney Cancer Quality Register DataEuropean Urology, 2011